June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
The Impact of Certolizumab Pegol Treatment on the Incidence of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis: Responses by Gender
Author Affiliations & Notes
  • Bengt Hoepken
    UCB Pharma, Monheim am Rhein, Germany
  • Irene van der Horst-Bruinsma
    Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Rianne van Bentum
    Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Frank D Verbraak
    Department of Ophthalmology, Amsterdam University Medical Center, Amsterdam, Netherlands
  • Thomas Rath
    St Franziskus-Hospital, Münster, Germany
  • James Rosenbaum
    Devers Eye Institute, Portland, Oregon, United States
    Oregon Health and Science University, Portland, Oregon, United States
  • Maria Misterska-Skóra
    Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland
  • Oscar Irvin-Sellers
    UCB Pharma, Slough, United Kingdom
  • Brenda VanLunen
    UCB Pharma, Raleigh, North Carolina, United States
  • Lars Bauer
    UCB Pharma, Monheim am Rhein, Germany
  • Martin Rudwaleit
    Klinikum Bielefeld and Charité Berlin, Berlin, Germany
    Gent University, Gent, Belgium
  • Footnotes
    Commercial Relationships   Bengt Hoepken, UCB Pharma (E); Irene van der Horst-Bruinsma, AbbVie (F), Bristol Myers-Squibb (F), MSD (F), Novartis (F), Pfizer (F), UCB Pharma (F); Rianne van Bentum, None; Frank Verbraak, Bayer (F), IDxDR (F), Novartis (F), UCB Pharma (F); Thomas Rath, AbbVie (C), Bristol Myers-Squibb (C), Chugai (C), Eli Lilly (C), MSD (C), Novartis (C), Pfizer (C), Roche (C), UCB Pharma (C); James Rosenbaum, AbbVie (C), Celldex (C), Corvus (C), Eyevensys (C), Gilead (C), Horizon (C), Janssen (C), Novartis (C), Pfizer (F), Roche (C), Santen (C), UCB Pharma (C), UptoDate (I); Maria Misterska-Skóra, None; Oscar Irvin-Sellers, UCB Pharma (E); Brenda VanLunen, UCB Pharma (E); Lars Bauer, UCB Pharma (E); Martin Rudwaleit, AbbVie (C), Bristol Myers-Squibb (C), Celgene (C), Eli Lilly (C), Janssen (C), MSD (C), Novartis (C), Pfizer (C), Roche (C), UCB Pharma (C)
  • Footnotes
    Support  This study was funded by UCB Pharma. Medical writing support from Costello Medical.
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3171. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bengt Hoepken, Irene van der Horst-Bruinsma, Rianne van Bentum, Frank D Verbraak, Thomas Rath, James Rosenbaum, Maria Misterska-Skóra, Oscar Irvin-Sellers, Brenda VanLunen, Lars Bauer, Martin Rudwaleit; The Impact of Certolizumab Pegol Treatment on the Incidence of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis: Responses by Gender. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3171.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Acute anterior uveitis (AAU) is the most common extra-articular manifestation in patients (pts) with axial spondyloarthritis (axSpA). Male pts have been shown to be more likely to develop AAU than female pts; however, data from interventional studies on AAU in axSpA comparing response to treatment by gender are scarce.1 Here, we report the impact of CZP treatment on AAU by gender in pts with active axSpA and a history of AAU from the C-VIEW study.

Methods : C-VIEW (NCT03020992) is an ongoing multicenter, open-label, phase 4 study. Pts had active axSpA, a history of recurrent AAU (≥2 AAU flares in total and ≥1 AAU flare in the year prior to study entry), and were HLA-B27 positive. Pts received CZP 400 mg at Weeks (Wks) 0/2/4, then 200 mg every 2 wks through 96 wks. A pre-specified interim analysis compared AAU incidence in the 48 wks prior to CZP treatment initiation with the 48 wks of treatment, using Poisson regression adjusted for possible within-patient correlations, with period (pre- and post-baseline) and axSpA disease duration as covariates. Incidence rates (IR) were calculated based on the number of cases per pt at risk over 48 wks. Outcomes by gender were analyzed post-hoc. Observed case data are reported; all p-values are nominal.

Results : Of 89 pts enrolled into the study, 56 were male and 33 were female; 85 pts completed treatment to Wk48. In the 48-wk pre-baseline period, the mean ± standard deviation (SD) number of AAU flares per pt was similar between male (1.3 ± 0.6) and female pts (1.4 ± 0.8). During 48 wks’ CZP treatment, the mean number of flares reduced in both groups to 0.2 ± 0.5 and 0.2 ± 0.4, respectively; using Poisson regression analysis, this represented a decrease in incidence from 1.5 to 0.2 in male pts (p<0.001), and 1.6 to 0.2 in female pts (p<0.001; Table). AAU flare incidence per 100 patient-years (PY) decreased from 145.6 to 17.7 per 100 PY in male pts, and from 148.2 to 20.5 per 100 PY in female pts (representing reductions of 88% and 86%, respectively).

Conclusions : CZP treatment led to a significant reduction in AAU flares in both male and female pts with axSpA and a history of recurrent AAU. Improvements in AAU incidence were similar between male and female pts.

References: 1. Smith WM. J Ophthalmol 2013;2013:928264.

This is a 2020 ARVO Annual Meeting abstract.

 

Impact of 48-week CZP treatment on AAU by gender

Impact of 48-week CZP treatment on AAU by gender

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×